Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.25 today
Chart and BID are shaping up nicely.
GLTA
Agreed. Just thinking Ebola could be a catalyst due to its sensationalism in the media right now.
In any case I believe we are on the right track and time will reveal that our inroads with partners like NIH, WHO and others will bring BJCT back to a definitive player in the NFIT space.
Nice to see some posters here, its been a bit quiet. :)
GLTA
Not just Ebola, but any vaccine. Most vaccines are either subcutaneous or intradermal and their technology is perfect for that.
Nice day today on a bad day for markets.
Looks like someone was interested in a few shares.
Closed at HOD.
GLTA
Anybody else think that the recent Ebola situation could really give companies like BJCT a shot in the arm, no pun intended.
NFIT's can greatly reduce the risk of needle pricks and provide a safer facilitation of vaccines and treatment options.
Maybe this will help get the FDA's head out of the stone age and start to actually help the public through the support of progressive technologies and treatments.
I know its wishful thinking.
GLTA
Nice find!
They seem to be securing countries successfully for distribution.
If the next Q shows more of the same revenue improvements we could be in for a decent PPS appreciation.
GLTA
Bioject Medical Technologies, Inc. (“Bioject”) and The Covenant Group announce the formation of Bioject Israel LTD
Sep 30, 2014, Tigard, OR/Los Angeles, CA - Bioject Medical Technologies, Inc. (“Bioject”) and The Covenant Group announce the formation of Bioject Israel LTD
Bioject Israel, LTD is the exclusive distributor of Bioject needle-free injection technologies in the State of Israel, providing a vital alternative to needle and syringe for the administration of liquid injectables.
“Despite the fact that needle free technology has been available for many years, it is only now gaining traction as a preferred method of administration in many parts of the world”, said Amir Ness, President of Bioject Israel, LTD. “There are numerous ways in which Bioject stands out as the leader in needle free technology. In the years ahead, I think we're going to start seeing rapid adoption of this technology. We look forward to introducing Bioject's array of devices to the Israeli market and working with companies at the forefront of medicine and healthcare."
Commented Mark Logomasini, Bioject’s President and CEO, “Having worked with Amir Ness on other ventures, we are very pleased that he has come aboard to represent Bioject in Israel. His knowledge of the region combined with his immersion in needle-free technology promises to be a highly effective combination and we look forward to a successful collaboration.”
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
The Covenant Group
Amir Ness
433 N. Camden Dr. Suite 400
Wow. Nice find.
Thanks for posting. :)
News today
Tigard, OR/Los Angeles, CA - Bioject Medical Technologies, Inc. (“Bioject”) and The Covenant Group announce the formation of Bioject Israel LTD
Bioject Israel, LTD is the exclusive distributor of Bioject needle-free injection technologies in the State of Israel, providing a vital alternative to needle and syringe for the administration of liquid injectables.
http://www.otcmarkets.com/stock/BJCT/news/Bioject-Israel--LTD?id=88772&b=y
Looks like whoever sold or shorted the stock last week is looking to cover back and the BID is above the current PPS.
Selling 150K shares moves the PPS about 10-15% but buying 150K shares will move it closer to 50%
The next piece of news should help put us into striking distance of .30 in my opinion.
GLTA
Someone is nibbling at the ASK.
$1 per share is a very real possibility as things progress short-term.
GLTA
Feels like something is brewing.
Hoping for news to kick off the new month.
GLTA
Hang on folks.. The tide has turned in my opinion and we are heading for bountiful waters.
JMO & GLTA
I'd say that Mark and Amir providing what appears to be a short-term bridge loan is quite compelling for the upside they see.
They could have gifted themselves a hefty interest rate but instead took just a 2% annual rate. Even though the loan seems to only have been necessary to bridge cash flow for 2 months or so.
Glad to see shareholder trust and integrity is being maintained.
This could be a great turnaround story.
GLTA & JMO
From the 8K:
Item 8.01 Other Events
On August 11, 2014, the Board of Directors of Bioject Medical Technologies, Inc. approved two secured notes for advances of capital made to Bioject, due to a cash flow shortfall in June 2014. The Mark A. Logomasini & Associates, Inc. SEP Fund (“SEP”) and Amir Ness advanced Bioject $100,000 and $50,000, respectively, on June 23, and June 25, 2014, respectfully, with the understanding that such short-term advances would have an interest rate similar to a factoring loan, would be secured by certain receivables of Bioject, in the case of Mr. Ness would be guaranteed by Mark Logomasini and the SEP would not incur losses. The notes have a simple, non-compounded monthly interest rate of 2% and mature on August 22, 2014.
A pretty impressive Q from a year of year perspective and considering revenues are up significantly from the last Q as well.
:)
GLTA
BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS
Tigard, OR – August 15, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the
second quarter ended June 30, 2014. The financial results are unaudited and actual results may vary.
~ Bioject reported revenues of $513,000 for the quarter ended June 30, 2014, compared to revenues of
$238,000 for the quarter ended June 30, 2013.
~ Operating expense was $788,000 for the second quarter of 2014, compared to $731,000 in the second quarter 2013.
~ Bioject reported an operating loss of $275,000 in the second quarter of 2014, compared to an operating loss of $493,000 in the second quarter of 2013. Net loss allocable to common shareholders for the second quarter of 2014 was $331,000, compared to $526,000 in the comparable 2013 period.
~ Basic and diluted net loss per share allocable to common shareholders for the quarter ended June 30, 2014 was $0.01 per share on 32.4 million weighted average shares outstanding compared to a net loss of $0.03 per share on 18.9 million weighted average shares outstanding for the same period in 2013.
~ For the six months ended June 30, 2014, Bioject reported revenues of $855,000, compared to revenues of $688,000 in the comparable period of 2013. Operating loss for the six months ended June 30, 2014 was $534,000, compared to $962,000 in the comparable period of 2013.
~ Net loss allocable to common shareholders was $647,000, or $0.03 per share, on 25.7 million weighted average shares outstanding in the six-month period ended June 30, 2014 compared to $1.0 million, or $0.05 per share, on 18.9 million weighted average shares outstanding in the comparable period of 2013.
Preferred share transactions that occurred in the first and second quarters of 2014 were described in prior 8-K filings.
Earnings in 2 weeks. If you count from last earnings release.
I believe they are working on a few things in the background and when they are ready there will be an update.
The new CFO should be in the thick of things by now.
GLTA & JMO
Volume uptick.. 80K plus and ASK was taken out.
Looks like someone is getting in before the crowds show up.
Looking forward to continued progress. :)
Needle-free: Bioject crafts injection tools
Thursday, 29 May 2014 01:00 | Written by Geoff Pursinger
It may seem like science fiction, but Tigard company says soon doctors won't use needles
If you ask Rick Stout, the future of medicine is located in a small office building on Southwest Sandburg Street.
It’s there that Stout and his colleagues at Bioject Medical Technologies have been developing what they see as the solution to a major problem: Syringes with sharp, pointy needles.
For more than two decades, Bioject has been making needle-free injection systems. Being able to give vaccinations or inject medication without needles not only prevents disease, Stout argues, it also helps children — who can be terrified of needles — to not be afraid of doctors.
“If you are a doctor in most parts of the world, the second kids see these long, scary needles, they literally hide,” said the company’s president, Mark Logomasini. “You can’t explain enough to them how beneficial that shot is and have kids come out and welcome the opportunity. It’s too scary.”
Needles have long been the standard for injections, said Stout, the company’s chief medical officer, but they have also been the cause of serious problems through the use of contaminated needles and challenges with disposing of the syringes after use.
“We know that there are patients at home injecting themselves every day with various medications, and that needle goes in a milk carton under the sink and then in the garbage at the end of the week,” Stout said. “It’s a global problem.”by: TIMES PHOTO: JONATHAN HOUSE - The Bioject device has no needle. Instead, it delivers liquid through a narrow, high-powered stream that penetrates the skin.
by: TIMES PHOTO: JONATHAN HOUSE - The Bioject device has no needle. Instead, it delivers liquid through a narrow, high-powered stream that penetrates the skin.
Change comes slowly
Instead of needles, Bioject’s devices are able to force medication into the skin using high-speed fluid.
Needle-free syringes are connected to an injector and pressed against the skin, where the medication is forced through a tube thinner than a human hair.
“In that syringe is $50 million worth of technology,” Logomasini said. “That’s the kind of investment that has gone into that product.”
With a soft hiss, mediation is delivered in less than a quarter of a second.
“They are faster, more reliable and also less painful,” Stout said. “By the time they are done making a joke with a child, the vaccination has been given, and they don’t realize it.”
The devices are also safer than needles because there’s no way to accidently prick yourself, Stout said.
“You can never spread infectious diseases with this,” Stout said, examining the small needle-less syringe. “There isn’t a way to spread it. If a child gets hold of this vial, they couldn’t re-use it. It has no value at all.”
It’s like something out of science fiction, he added.
“It’s very ‘Star Wars,’” Stout said. “It’s very creative and very new.”
Bioject’s devices have been used in Hollywood films. “Batman Begins” used one of Bioject’s devices to cure people of a brain-altering toxin.
“We’re pretty proud of that,” Stout said.
But changing old habits is hard. Doctors have been using needles to give injections for centuries, Stout said. Getting people to adopt a new technology can be a tough sell.
“It takes a long time for clinicians, doctors and nurses to convert to something different,” Stout said. “Once they start to convert, it becomes natural to them, but that takes time.”
The biggest hurdle for the company so far, Logomasini said, is the price.
“A needle costs about a nickel to make. Our device lasts forever, but each syringe costs about a dollar,” Logomasini said. “That’s a 20-fold difference. You have to be able to justify that.”
Logomasini said if injuries caused by needles were factored in, the cost between needle-free devices and traditional syringes is about even.
“The accidental injection or cross-contamination of an unintended patient with a dirty needle, or the potential of hepatitis or HIV are so much greater,” he said. “That cost is spread out and covered by insurance companies. Nobody ever sees that affect.”by: TIMES PHOTO: JONATHAN HOUSE - Rick Stout, head medical officer for Bioject, shows how a liquid is delivered through the skin of a patient with the company's needle-free injection device.
by: TIMES PHOTO: JONATHAN HOUSE - Rick Stout, head medical officer for Bioject, shows how a liquid is delivered through the skin of a patient with the company's needle-free injection device.
Global focus
Until a few years ago, the company employed about 100 people at its world headquarters in Tualatin.
From there, the company manufactured and sold devices all across the country.
But that changed in October 2011, Logomasini said, when the Federal Drug Agency issued warnings to people about not trusting needle-free devices to get flu shots.
The FDA said needle-free companies should run clinical trials on each vaccine to prove that its devices could be used safely in each instance.
It was a small change, but Logomasini said it has had big impacts.
“We went from 100 people in Tualatin to about 10 people in Tigard,” Logomasini said. “It turned the tables against Bioject and against vaccine companies. Most people don’t understand the drug development process. It’s a bit like shooting craps, blindfolded, and with only one dice. It is that hard to get something from the concept phase to commercial approval. So adding that additional element of risk for needle-free technology was enough.”
Today, Logomasini said the company does about half of its work outside of the country in Africa, South America and Asia.
“There’s an old Yogi Berra quote ‘Hit ‘em where they ain’t,’” Logomasini said. “That’s what we’re doing.”
The company works with groups such as the World Health Organization and the Centers for Disease Control and Prevention.
“Frankly, the regulatory hurdles here are at a point where we needed to go to places where needle-stick injuries are recognized as the public health catastrophe that they are,” Logomasini said
Bioject wants to corner a very specific market, Logomasini said: Parts of the world where the risk of needle-stick infections is high, but also with a growing middle class able to afford the devices.
“On the surface you ask, ‘How big can that market actually be?’ But the percentage basis of your adoption rate can be zero-point-something percent there, and the sales volume can be huge.”
This month the company announced that it would begin selling its devices in China due to an agreement with a pharmaceutical drug company with ties in the area.
“We have an office in Kazakhstan, we have an office in Nigeria. That’s where the emphasis is right now,” Logomasini said.
Clinicians are able to inoculate whole villages without the risk of cross-contamination, and the needle-free environments help children be more comfortable, Stout said.
“I’d like to see the company continue to grow globally,” he said. “We have been pretty focused on the U.S. market for many years, but now I do lot of my work in India, Africa, Singapore, etc.”
In the next 10 years, Stout said needle-free syringes will become more popular and will help to keep people all around the world healthier.
“It’s a disaster,” Stout said. “We have to get rid of them. We have to get them out of these high-risk areas.”
Looks like a good pick-up. Christine was a loyal and valuable team member as VP of Finance.
I think Mr. Chow brings a more comprehensive understanding of SEC filings and also relationship tenure with Asian contacts.
The price is right and it gives BJCT time to assess his contribution with an incentive instead of guaranteed salary.
Lets get this thing rocking!
GLTA
New 8K out!
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On July 1, 2014 Bioject Medical Technologies Inc. (the “Company”) announced the departure of Christine M. Farrell, Vice President of
Finance and the appointment of Tony K. Chow, age 65, as the Company’s Chief Financial Officer and Corporate Secretary.
From 1999 to 2013 prior to joining the Company, Mr. Chow was a consultant in financial and operational management roles for domestic and international companies. Mr. Chow consulted in the areas of SEC reporting, financial/IT/J-SOX compliance reporting, and internal/external audits on a project or interim basis. Most recently, Mr. Chow was the Chief Financial Officer at American Laser Healthcare Corporation, a development stage medical device company with SEC reporting. Mr. Chow brings professional services experience with over 30 years in financial management consulting, financial operations including SEC reporting, financial/IT/J SOX compliance, business development, client relationship management, and software product development/implementations.
From 1997 to 1999, Mr. Chow was the Director of Asia Sales and Marketing at Digital Video Systems, Inc.
From 1994 to 1997, Mr. Chow was the Chief Financial Officer and Corporate Controller at Craig Consumer Electronics, Inc.
From 1989 to 1993, Mr. Chow was the Controller of InterTherapy, Inc., a start-up company in the manufacturing and marketing on intravasculathreer ultrasound imaging system and catheter. Mr. Chow holds an MBA degree in Finance, Accounting and Operations Research from the University of California at Riverside. He also earned a BA degree in Economics from the University of the Pacific at Stockton, and a BA degree in Physiology from the University of California at Berkeley.
Pursuant to the Agreement, Mr. Chow will formally serve as the Company’s Chief Financial Officer of the Company effective July 1, 2014 and he will receive an annual salary of $90,000 subject to review at December 31, 2014. It is anticipated that Mr. Chow’s salary will be adjusted upward to market rates, if the financial condition of the Company improves.
Mr. Chow will be eligible for stock option grants and other incentive compensation as determined by the Board of Directors of the Company. This Agreement has an initial term of one (1) year, subject to the early termination provisions set forth in the Agreement. Upon expiration of the initial term, this Agreement will be automatically extended for additional one-year terms unless Mr. Chow or the Company shall, upon 120 days written notice to the other, elect not to extend this Agreement for an additional one-year term.
I would prefer to see a reputable Chinese distributor.
Even just securing distribution in China could be worth north of $1 a share.
Lots of huge markets still to open up.
Keep an eye on the M&A activity for companies like COV, Cardinal, GE in the medical device space. They love eating up smaller companies that have done all the leg work to establish global demand for devices/technologies like our.
Asia is heating up, and it would make sense for them to grab BJCT. I would like to see $1-$2 for all the patent value.
I heard there was a potential buyout a year or so ago from interested Asian parties. The deal fell through apparently at the last minute which could be a blessing in disguise now for shareholders as the company has made some good strides.
Perhaps a renewed interest?
Or someone just seeing some value/opportunity in what BJCT is doing.
Either way its nice to see some volume and PPS appreciation.
GLTA
Wouldn't it be interesting if some Asian investors (say, influenced by what they saw at the conference) started picking up some stock?
She's moving folks.
Bid at .21 and the Ask at .25
Something must be brewing from the Singapore conference.
GO BJCT!
Slight pullback today. Healthy for the bid/ask.
Need it to narrow a bit. Hopefully get a push soon from events at the conference.
GLTA
Now .18
ASK moved up to .195
Accumulation..
.169 printed
Someone is getting a few.
BID up to .155 / ASK at .16
Seminar is on!
GLTA
Decent action today. Look for more come Monday.
Things are looking up.
BJCT.
BID is now at .15
PPS is back to .15 and ASK is moving up.
Could be some significant and material news out of the conference coming up.
Stay tuned..
GLTA
Bid has increased to .14 and if we can get through the .15/.16 level we should be clear to run for a bit.
This conference can be the catalyst we have been waiting for. Once we lock up global distribution we can move forward with sales, marketing and more R&D.
Bioject to Participate in World Vaccine Congress – Asia in Singapore June 9-12th
Tigard, OR –May27, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer of needle-free injection systems announces participation in the World Vaccine Congress - Asia in Singapore June 9 – 12th. Bioject will be presenting its technology to vaccine company delegates, public health officials, and developers from throughout the region. Attending the conference will be Mark Logomasini, President and CEO and Dr. Richard Stout, Executive Vice President and Chief Medical Officer. In conjunction with the activities at the conference, Bioject will be hosting its first international distributor meeting.
“We are looking forward to the opportunities this forum provides for Bioject to present and discuss our technology with senior vaccine attendees across Asia who will be present at this event,” said Mark Logomasini, Bioject’s President and CEO. “In addition to our presence, our distributors covering all of the countries, companies, and organizations will also be in attendance at the conference. Their involvement will help to formulate and execute on strategies to increase awareness and sales in these key markets.”
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle- free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
For more information about Bioject visit www.bioject.com.
Lowered operating expenses by 30%, cut losses by 40%, maintained decent revenues during transitionary period.
Overall it was a decent Q with new distributors appointed for an expansion of the international network. Once they take hold revenues will climb. Company is projected to bring in 1.4M in revenues based on this Q1, not too shabby.
JMO & GLTA
BIOJECT REPORTS UNAUDITED FIRST QUARTER 2014 FINANCIAL RESULTS
Tigard, OR – May 15, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), an innovative developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the first quarter ended March 31, 2014. The financial results are unaudited and actual results may vary.
• Revenue for the first quarter ended March 31, 2014 was $341,000, compared to $450,000 in the comparable quarter of 2013;
• Operating expense for first quarter of 2014 was $601,000 compared to $919,000 in the 2013 quarter;
• Operating loss for the first quarter of was $260,000, compared to $469,000 in the 2013 quarter; and
• Net loss allocable to common shareholders for the 2014 quarter was $316,000, or $0.02 per share on 18.9 million weighted average shares outstanding, compared to a net loss allocable to common shareholders of $502,000, or $0.03 on 18.9 million weighted average shares outstanding for the same period last year.
Results for the first quarter ended March 31, 2014, do not reflect the impact of the Company’s restructuring, which closed on April 30, 2014. See the Company’s 8-K dated May 6, 2014, for further information on the restructuring.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
1$ is an inflection point. Once it reaches that level we will attract a whole new kind of investor.
I believe the float must be 90% owned by insiders.
Its hard to get shares without running up the ASK which is why we got to .50 with relatively little volume.
The CEO is working hard and seems to be squarely focused on making BJCT a winner. Glad to be along for the ride here right now.
May grab a few more during the summer.
JMO & GLTA
I'm thinking more than $1. After all, it went to almost 50 cents on nothing at all
LOL.
Yes. China! Even a fraction of this market would send Bioject to 1$.
GLTA
The prospects of serving a market with over a billion people is a huge opportunity to say the least.
This is going to catch fire and when it does. LOOK OUT.
Needless tech is the way of the future. Cant deny it. Its quite possible to see Bioject be the a takeout target once things ramp up.
It would be peanuts for a COV or Cardinal to pay 1$ or more per share.
JMO & GLTA
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
821
|
Created
|
10/10/08
|
Type
|
Free
|
Moderators |
Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc. (OTCBB: BJCT) is an emerging drug delivery company developing the world's leading technology for needle-free injection of liquid medications.
Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. Since then, Bioject has developed a broad technology platform for delivering many different types of medications and vaccines to the subcutaneous and intramuscular depths. The company is currently developing systems and is in clinical trials for intradermal injections.
Bioject has developed a portfolio of injection systems based on its core technology. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing an inexpensive, pre-filled, disposable injection systems. Bioject's strategy is to form strategic partnerships with leading pharmaceutical, biotechnology, and animal health companies. The company seeks to develop mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of the partner's injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies.
Bioject Medical Technologies Inc.
20245 SW 95th Avenue
Tualatin, OR 97062
Phone: 503-692-8001
Fax: 503-692-6698
E-mail: investorrelations@bioject.com
Web: www.bioject.com
Bioject Medical Technologies Inc.is a fully reporting OTCBB stock: www.otcmarkets.com/pink/quote/quote.jsp
The company has recently confirmed that the share structure from the latest 10Q (3rd Quarter 2009) is still accurate: www.otcmarkets.com/edgar/GetFilingPdf
A/S: 100,000,000
O/S: 17,679,111 (confirmed by T/A on 4th March 2010)
Float: 13,800,000
The company has stated that at the current time they do not have any plans to dilute, as they recently closed a financing agreement with their largest shareholder. In the event they do need to dilute they would do it as a private placement which is usually done in the form of restricted shares that can not convert to common for 6 months, so we do not need to worry about dilution.
Transfer Agent
American Stock Transfer & Trust Company, LLC
59 Maiden Lane
Plaza Level
New York, NY 1003
Tel: (800) 937-5449 or (718) 921-8124
Web: www.amstock.com
Estimated Market Cap: $3,345,872 as of Mar 2, 2010
The Form 8K filed with the SEC for the company's financial year ending December 31st 2009 can be viewed here: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7133612
.
April 7th 2010: Bioject announces that it has met the final milestone under its Development Agreement with Merial Limited ("Merial") by delivering devices with auto-disable nozzles to Merial for its next generation spring-powered companion animal vaccination device. Bioject's President and Chief Executive Officer, Ralph Makar said "Merial has been an excellent partner and we appreciate the confidence Merial has in our needle-free technology. We are pleased to have completed this final milestone and look forward to using our new platform technology in its first commercial application". Full press release www.businesswire.com/portal/site/home/permalink/
March 17th 2010: Bioject published 4th Quarter and End of Year 2009 financials showing that the operating loss and net loss allocatable to common shareholders has decreased by 65% over the previous financial year. Bioject's President and Chief Executive Officer, Ralph Makar said "Recent positive events, such as the announcement of our strategic alliance with MPI Research, the elimination of our existing debt and the additional cash infusion, are encouraging as we strive for a better future and to increase shareholder value". Full press release http://www.marketwatch.com/story/bioject-reports-december-31-2009-results-2010-03-17?reflink=MW_news_stmp
February 22nd 2010: Bioject announced in a PR approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI) to be delivered to healthy volunteers by ZetaJet® Full press release www.businesswire.com/portal/site/home/permalink/
February 16th 2010: Bioject announced in a PR full USDA license approval for Oncept canine melanoma vaccine, to be administered via a Canine Transdermal Device, which delivers the vaccine without the use of a needle. The device was developed in conjunction with Bioject, Inc. Full press release www.prnewswire.com/news-releases/merial-receives-full-license-approval-for-oncepttm-canine-melanoma-vaccine-84464667.html
January 5th 2010: Bioject announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics, which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research. Full press release www.businesswire.com/portal/site/home/permalink/
December 21st 2009: Bioject announced it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the “LOF”), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share. Gross proceeds from the sale were $1,201,834, payable by payment of $500,000 in cash and the cancellation of the $600,000 outstanding principal amount of and $101,834 accrued interest. Full press release www.businesswire.com/portal/site/home/permalink/
April 6th 2009: Bioject announced that the U.S. Food and Drug Administration (FDA) has granted market clearance for the Zetajet™ Needle-Free Injection Therapy System. Bioject’s new ZetajetTM system is the latest advance in needle-free delivery systems, offering a significant array of unique product features and patient benefits that can provide highly competitive differentiation to a wide variety of injectables market segments. Full press release www.businesswire.com/portal/site/google/
************************************************************************************************************************************************************************************
Results from a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children. The study commenced in October 2006 and was completed in November 2009, with study completion date set for May 2010. Good results from this study could be amazing for BJCT investors.
Clinical trials information www.clinicaltrials.gov/ct2/show/NCT00386542
Bioject's needle-free injection technology works by forcing liquid medication at high speed through a tiny orifice that is held against the skin. The diameter of the orifice is smaller than the diameter of a human hair. This creates an ultra-fine stream of high-pressure fluid that penetrates the skin without using a needle.
Bioject's technology is unique because it delivers injections to a number of injection depths and supports a wide range of injection volumes. For instance, the Biojector 2000 can deliver intramuscular or subcutaneous injections up to 1 mL in volume. In addition, Bioject is developing a syringe for the Biojector 2000 that delivers intradermal injections that is currently in clinical trials.
Intradermal* injections are very shallow injections that deposit the medication between the layers of the skin. Many new DNA-based vaccines are delivered to the intradermal layer.
Subcutaneous injections are delivered to the adipose (fat) layer just below the skin. Many therapeutic proteins are delivered to the subcutaneous depth, such as human growth hormone.
Intramuscular injections are the deepest injection type, delivering the medication into the muscle tissue. Most vaccines are currently delivered to the intramuscular depth.
The Bioject research and development team has developed a new spring-powered injector known as the ZetajetTM, which is based on the design of the Biojector® 2000 (B2000) for performance but uses a spring for its power source. The pressure profile of the Zetajet has been documented by in vitro testing to be virtually the same as that of the B2000, which has given millions of injections. The B2000 is a needle-free jet injection device that provides up-to-date jet injection technology and eliminates or reduces complications associated with others previous devices (eg, cross-contamination from patient to patient, lacerations at the injection site, difficult device cleaning, cumbersome tanks, etc).1-12 The intended use of this device is to provide a low-cost, needle-free injection system that delivers SC, IM, or ID injections via a simple change of the syringe. There is no need to adjust the device or technique for different injection types. This new needle-free system offers an additional feature - an auto-disable syringe that prevents re-use of the syringe. The syringe may be used to perform reconstitution with manual movement of the syringe plunger; however, once the injection is given, the syringe is disabled with the plunger tip remaining in the syringe to prevent any possible re-use.
A study comparing the use of Zetajet was conducted at a clinical centre in 2009. After meeting all eligibility criteria, a total of 60 healthy subjects were enrolled in this study and were given three injections. After each injection, a subjective evaluation was made related to the injection site, and questions were asked regarding the patients’ perceptions of the injection. Immediately after each injection, the injection sites were evaluated by a trained healthcare professional and within 5 minutes after the injections, the degree of pain with each injection was elicited from the subjects. The injection sites were also evaluated immediately following for local reactions (bruising, redness, and wheal formation). The follow-up was completed 24 hours after the initial injection and consisted of injection site evaluations.
The study reconfirmed the capability of a spring-powered device to successfully provide three types of injection (SC, ID, IM) that was originally proven using the Vitavax, a precursor device that led to the development of the Zetajet. The device was well received by the clinical investigators and clinicians who used the device during the study. Comments received throughout the trial regarding the ease of winding, loading, and administering the injection by the clinical investigators was very positive. On the assessments by injection type, all three injection methods with Zetajet received very positive ratings with more than 96% overall receiving Extremely Favorable and Favorable ratings.
In conclusion, the results of this clinical trial indicate that the Zetajet needle-free injection system is preferred compared to a traditional needle and syringe system. It also demonstrated the subjective injection effectiveness of the Zetajet jet injection system for SC, ID, and IM injections.With these unique advances in delivery technology, the Zetajet is anticipated to provide the optimal injection therapy system for both developed and developing countries to provide a safer and more effective method for delivering their parenteral injectables.
The full study report can be downloaded here http://www.bioject.com/pdf/Zetajet%20DDT%20Article%20February%202009%20Low%20Res.pdf
The Biojector® 2000 is a durable, professional-grade injection system designed for healthcare providers. The Biojector® 2000 is the only needle-free system in the world cleared by the FDA to deliver intramuscular injections. The system can also deliver subcutaneous injections, and is being used for intradermal injections in clinical trials.
Cool.clickTM is a needle-free injection system designed for delivery of Saizen® recombinant human growth hormone. Serono, the manufacturer of Saizen, is the first company to offer a needle-free delivery system for human growth hormone injection that is cleared by the FDA.
SeroJetTM needle-free injection system designed for delivery of Serostim, Serono’s high-dose recombinant human growth hormone formulation that is the leading treatment for AIDS wasting. Serostim has been the most extensively tested in AIDS wasting and the only biotechnology-derived drug approved for AIDS wasting by the FDA in the USA, which has granted Serostim orphan drug status, and marketing exclusivity, in the United States until August 2003.
The Vial Adapter Drug Reconstitution Adapter Kit includes a blunt plastic device that replaces a fill needle for accessing medication vials, making syringe filling completely needle-free. The Vial adapter is designed to fit all standard syringes and all standard 13mm vials. The system is a convenient method for the withdrawal of medication and the transfer of diluents for reconstitution without the use of a needle.
The Bioject® needle-free drug reconstitution vial adapter is a non-sharp plastic device that replaces a fill needle for accessing medication vials making syringe filling completely needle-free. The vial adapter is designed to fit all standard syringes and fits on a drug vial with a 13 mm neck. The system is a convenient method for the withdrawal of medication and the transfer of diluents for reconstitution without the use of a needle.
Please mark this board as a favorite and let's get more eyeballs here!
Suggestions for improvements and updates to the iBox are welcomed. PM Rick-UK with your ideas!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |